VEGFA and breast cancer: However, one group Schneider et al., (2008) has identified an association between VEGF promoter polymorphisms and breast cancer response to Bevicuzimab, with genotypes consistent with haplotype 4 associated with dramatic extension of overall survival similarly in our a significant correlation between VEGF-A rs833061 genotypes in breast cancer patients with respect Tamoxifen treatment was revealed (p=0.005) and also a significant association of VEGF-A (-460T>C) genotypes in breast cancer patients with Trastuzumab or herceptin treatment was reported (p=0.03).